急性髓系白血病患者骨髓溶血磷脂酰胆碱酰基转移酶1的表达分析

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (886 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective:To explore the expression status of lysophosphatidylcholine acyltransferase 1 (LPCAT1) gene and its clinical significance in patients with acute myeloid leukemia (AML). Methods:Quantitative realtime PCR was used to examine the LPCAT1 mRNA expression in bone marrow samples from 60 primary AML patients and 27 healthy donors. Results: LPCAT1 mRNA expression was significant lower in AML than controls(P<0.001). LPCAT1 mRNA lowexpression was found in 27 (45%) of 60 AML cases but none in the 27 controls, the difference was statistically significant (χ2=17.618,P<0.001).There was no correlation between the lowexpression of LPCAT1 mRNA with the age, sex, white blood cell count, platelet count, hemoglobin concentration, FAB subtypes and AML karyotypic groups (P>0.05). The receiver operating characteristic (ROC) curve revealed LPCAT1 mRNA expression might serve as a potential diagnostic marker for differentiating AML from controls with an area under the ROC curve of 0.896 (95% CI:0.825~0.967, P<0.001). At the cutoff value of 0.173 of LPCAT1 mRNA expression, the sensitivity and the specificity were 88.3% and 81.5%, respectively.Conclusion: LPCAT1 lowexpression is a frequent molecular event in AML, and it may be used to assist the diagnosis of AML.

Received: 20 August 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Qin1
	XU Zijun1
	LIN Jiang1
	QIAN Jun2
	QIAN Wei3

Cite this article:

CHEN Qin1,XU Zijun1,LIN Jiang1等.

Expression analysis of lysophosphatidylcholine acyltransferase 1 gene in patients with acute myeloid leukemia

[J]. Journal of Jiangsu University(Medicine Edition), 2022, 22(1): 50-53.

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2022/V22/I1/50

［1］Santos CR, Schulze A. Lipid metabolism in cancer［J］. FEBS J, 2012, 279 (15): 2610-2623.

［2］Grupp K, Sanader S, Sirma H, et al. High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers［J］. Mol Oncol, 2013, 7(6): 1001-1011.

［3］Zhou X, Lawrence TJ, He Z, et al. The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer［J］. Exp Mol Pathol, 2012, 92(1): 105-110.

［4］ShidaSakazume T, EndoSakamoto Y, Unozawa M, et al. Lysophosphatidylcholine acyltransferase 1 overexpression promotes oral squamous cell carcinoma progression via enhanced biosynthesis of plateletactivating factor［J］. PLoS One, 2015, 10(3): e0120143.

［5］Morita Y, Sakaguchi T, Ikegami K, et al. Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression［J］. J Hepatol, 2013, 59(2): 292-299.

［6］Lebok P, von Hassel A, Meiners J, et al. Upregulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer［J］. Aging (Albany NY), 2019, 11(18): 7796-7804.

［7］Abdelzaher E, Mostafa MF. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence［J］. Tumour Biol, 2015, 36(7): 5473-5483.

［8］Wei C, Dong X, Lu H, et al. LPCAT1 promotes brain metastasis of lung adenocarcinoma by upregulating PI3K/AKT/MYC pathway［J］. J Exp Clin Cancer Res, 2019, 38(1): 95.

［9］Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the FrenchAmericanBritish Cooperative Group［J］. Ann Intern Med, 1985, 103(4): 620-625.

［10］Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms［J］. Blood, 2002, 100(7): 2292-2302.

［11］陈星星,钱军,林江,等.急性髓系白血病CTNNA1基因的表达及临床意义［J］.江苏大学学报（医学版）,2014, 24(1): 52-55, 58.

［12］Wang K, Wu Z, Si Y, et al. Identification of LPCAT1 expression as a potential prognostic biomarker guiding treatment choice in acute myeloid leukemia［J］. Oncol Lett, 2021, 21(2): 105.

［13］Luo X, Xu L, Wu X, et al. Decreased SATB1 expression promotes AML cell proliferation through NFκB activation［J］. Cancer Cell Int, 2019, 19: 134.

［14］ZareAbdollahi D, Safari S, Movafagh A, et al. Intact expression status of RASSF1A in acute myeloid leukemia［J］. Med Oncol, 2014, 31(1): 770.

［15］Pietrzak J, Mirowski M, Jeleń A, et al. Decreased MMP1 gene expression in acute myeloid leukaemia［J］. Mol Biol Rep, 2019, 46(2): 2293-2298.